Literature DB >> 3607781

Interaction of etoposide and cisplatin in an in vitro tumor model.

R E Durand, J H Goldie.   

Abstract

Some clinical data suggest that etoposide and cisplatin may be synergistic against certain types of tumors. Since studies of the process are both easier and more precise in laboratory systems, we have used V79 spheroids as a model to quantify the interaction of the drugs in cycling and noncycling, aerobic, and hypoxic cell subpopulations. The degree of interaction between etoposide and cisplatin in this system, quantified using the median-effect analysis, was highly dependent on the overall treatment toxicity, and to a lesser extent, the subpopulation of cells assessed. Synergism was demonstrated for relatively modest (1 decade) cell kills achievable at clinically relevant drug doses; increasing the toxicity of the combination treatment by increasing the cisplatin level produced a greater relative gain in the noncycling and hypoxic cells than in the aerobic, cycling cells of the spheroids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3607781

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  14 in total

1.  Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.

Authors:  G Nocentini; A Barzi; P Franchetti
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Modification of the 8 drugs in 1 day regimen: feasibility of substitution of other agents.

Authors:  K W Chan; C J Fryer; P Steinbok
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

Review 3.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

4.  Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

Authors:  Huw D Thomas; David J Porter; Imke Bartelink; Joy R Nobbs; Michael Cole; Suzie Elliott; David R Newell; A Hilary Calvert; Martin Highley; Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

5.  Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.

Authors:  J Walewski; J Romejko-Jarosińska; J Zwoliński; S Falkowski; P Siedlecki
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

6.  Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors.

Authors:  N Viñolas; F Graus; B Mellado; L Caralt; J Estapé
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

7.  Relationships between various uses of antineoplastic drug-interaction terms.

Authors:  G L Wampler; W H Carter; E D Campbell; P A Keefe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors.

Authors:  B J Corden; L C Strauss; T Killmond; B S Carson; M D Wharam; A J Kumar; S Piantadosi; P A Robb; P C Phillips
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

9.  Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.

Authors:  S S Daoud; N H Forde
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.

Authors:  Lisa M McGregor; Sheri L Spunt; Victor M Santana; Clinton F Stewart; Deborah A Ward; Amy Watkins; Fred H Laningham; Percy Ivy; Wayne L Furman; Maryam Fouladi
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.